Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Faron Pharmaceuticals Oy. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Faron Pharmaceuticals Oy's
is considered below, and whether this is a fair price.
Price based on past earnings
Faron Pharmaceuticals Oy's earnings available for a low price, and how does
this compare to other companies in the same industry?
Unable to determine if Faron Pharmaceuticals Oy is high growth as no earnings estimate data is available.
Faron Pharmaceuticals Oy's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Faron Pharmaceuticals Oy's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Faron Pharmaceuticals Oy
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Faron Pharmaceuticals Oy's finances.
The net worth of a company is the difference between its assets and liabilities.
Faron Pharmaceuticals Oy is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Faron Pharmaceuticals Oy's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Faron Pharmaceuticals Oy's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 3.2x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Prof. Markku Jalkanen, Ph.D., serves as a Partner and Advisor at Inveni Capital. Prof. Jalkanen founded Faron Pharmaceuticals Corp. (formerly Faron Pharmaceuticals Ltd.) in 2006 and Chief Executive Officer since 2007 and served as its President since 2007. Prof. Jalkanen has been an Executive Director of Faron Pharmaceuticals Oy since October 24, 2006. He is one of Finland's biotechnology pioneers and was the Founder and Chief Executive Officer at Biotie Therapies Corp. in Finland. He has also held several Interim Chief Executive Officer, Board and Advisor positions in Finnish life science companies and related public organizations. Prof. Jalkanen served as Chairman of OY LX Therapies Ltd. Prof. Jalkanen has a strong international science background with more than 130 peer reviewed publications. Dr Jalkanen obtained a Masters in Medical Biochemistry from the University of Kuopio in 1977 and subsequently received a PhD in Medical Biochemistry from the University of Turku in 1982. Dr Jalkanen completed a side-laudatur examination in Molecular Biology from the University of Turku in 1981 and completed his post doctoral training at Stanford University, California between 1983 and 1986. Dr Jalkanen obtained the position of docent in Biochemistry from the University of Helsinki and the same qualification in Molecular and Cell Biology from the University of Turku in 1987 and 1992 respectively. Dr Jalkanen became a Professor at the University of Turku in January 1992.
Markku's compensation has increased whilst company is loss making.
Markku's remuneration is lower than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure
Average tenure and age of the
Faron Pharmaceuticals Oy
management team in years:
The average tenure for the Faron Pharmaceuticals Oy management team is less than 2 years, this suggests a new team.
Yrjö Erik Wichmann
Vice President of Financing & Investor Relations
Chief Development Officer
Chief Financial Officer
Vice President of Operations
Chief Medical Officer & VP of Drug Development
Chief Commercial Officer
Board of Directors Tenure
Average tenure and age of the
Faron Pharmaceuticals Oy
board of directors in years:
The tenure for the Faron Pharmaceuticals Oy board of directors is about average.
Board of Directors
Jonathan Kenneth Knowles
Chairman of Clevegen Scientific Advisory Board
Who owns this company?
Recent Insider Trading
No 3 month individual insider trading information.
How Much Of Faron Pharmaceuticals Oy (LON:FARN) Do Insiders Own?
Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … Faron Pharmaceuticals Oy is a smaller company with a market capitalization of UK£21m, so it may still be flying under the radar of many institutional investors. … Taking a look at our data on the ownership groups (below), it's seems that.
Is Faron Pharmaceuticals Oy's (LON:FARN) CEO Salary Justified?
This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Markku Jalkanen's Compensation Compare With Similar Sized Companies. … Our data indicates that Faron Pharmaceuticals Oy is worth UK£17m, and total annual CEO compensation is €281k.
Should You Be Concerned About Faron Pharmaceuticals Oy's (LON:FARN) Shareholders?
In this analysis, my focus will be on developing a perspective on Faron Pharmaceuticals Oy’s (LON:FARN) latest ownership structure, a less discussed, but important factor. … Therefore, it is beneficial for us to examine FARN's ownership structure in more detail. … See our latest analysis for Faron Pharmaceuticals Oy
Before You Buy Faron Pharmaceuticals Oy's (LON:FARN), Consider This
Faron Pharmaceuticals Oy has a beta of 1.04, which means that the percentage change in its stock value will be higher than the entire market in times of booms and busts. … A high level of beta means investors face higher risk associated with potential gains and losses driven by market movements. … However, this is the opposite to what FARN’s actual beta value suggests, which is higher stock volatility relative to the market.
Cash management is still not optimal and should be improved, but its overall debt level and interest coverage somewhat reduces my concerns around the sustainability of the business going forward. … One reason I do like FARN as a business is its low level of fixed assets on its balance sheet (9.46% of total assets). … FARN has virtually no fixed assets, which minimizes its downside risk.
Faron Pharmaceuticals Oy (LON:FARN): Does The -72.28% Earnings Drop Reflect A Longer Term Trend?
Examining Faron Pharmaceuticals Oy's (AIM:FARN) past track record of performance is an insightful exercise for investors. … Check out our latest analysis for Faron Pharmaceuticals Oy How Did FARN's Recent Performance Stack Up Against Its Past? … Though Faron Pharmaceuticals Oy's past data is helpful, it is only one aspect of my investment thesis.
Faron Pharmaceuticals Oy (AIM:FARN): Should The Recent EPS Drop Worry You?
Examining Faron Pharmaceuticals Oy's (AIM:FARN) past track record of performance is an insightful exercise for investors. … Check out our latest analysis for Faron Pharmaceuticals Oy Was FARN's recent earnings decline worse than the long-term trend and the industry? … Faron Pharmaceuticals Oy's track record can be a valuable insight into its earnings performance, but it certainly doesn't tell the whole story.
Faron Pharmaceuticals Oy (AIM:FARN): How Much Growth Is Left In Healthcare?
Moreover, the trend of below-industry growth rate is expected to continue in the future with FARN poised to deliver a -10.86% growth compared to the industry average growth rate of 32.43%. … FARN is a biotech industry laggard in terms of its future growth outlook. … If your initial investment thesis is around the growth prospects of FARN, there are other biotech companies that are expected to deliver higher growth in the future, and perhaps trading at a discount to the industry average.
Why Faron Pharmaceuticals Oy's (AIM:FARN) CEO Pay Check Matters To You
Over the last year FARN released negative earnings of -£13M , which is a further decline from prior year's loss of -£7M. … Despite the fact that one size does not fit all, as compensation should account for specific factors of the company and market, we can estimate a high-level benchmark to see if FARN deviates substantially from its peers. … Usually I'd use market cap and profit as factors determining performance, however, FARN's negative earnings reduces the effectiveness of this method.
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute organ traumas, vascular damage, and cancer immunotherapy. The company’s lead product candidate is Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS). It also develops Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.